These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32631250)

  • 1. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.
    Hansen HH; Ægidius HM; Oró D; Evers SS; Heebøll S; Eriksen PL; Thomsen KL; Bengtsson A; Veidal SS; Feigh M; Suppli MP; Knop FK; Grønbæk H; Miranda D; Trevaskis JL; Vrang N; Jelsing J; Rigbolt KTG
    BMC Gastroenterol; 2020 Jul; 20(1):210. PubMed ID: 32631250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
    Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
    Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
    World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Flensted-Jensen M; Oró D; Rørbeck EA; Zhang C; Madsen MR; Madsen AN; Norlin J; Feigh M; Larsen S; Hansen HH
    BMC Gastroenterol; 2024 Feb; 24(1):59. PubMed ID: 38308212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
    PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.
    Asgharpour A; Cazanave SC; Pacana T; Seneshaw M; Vincent R; Banini BA; Kumar DP; Daita K; Min HK; Mirshahi F; Bedossa P; Sun X; Hoshida Y; Koduru SV; Contaifer D; Warncke UO; Wijesinghe DS; Sanyal AJ
    J Hepatol; 2016 Sep; 65(3):579-88. PubMed ID: 27261415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
    BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    Hymel E; Vlock E; Fisher KW; Farazi PA
    PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
    Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.